London[email protected] | +44 20 3 465 1201 | v-Card
Stephanie Léouzon is a Managing Director in Stifel’s Global Healthcare Group. She has worked on over 100 strategic and financing transactions in the biopharmaceutical industry, with an aggregate value of over $75 billion. She joined Stifel in 2023 through the Torreya acquisition. At Torreya, Stephanie held the roles of Partner and Head of Europe. Prior to joining Torreya in 2011, Stephanie was a Managing Director and Senior Advisor at Credit Suisse in London. She was a Director in Healthcare Investment Banking at Salomon Brothers, and a Vice President in Investment Banking at JP Morgan and Lehman Brothers in New York.Highlights of Stephanie’s strategic advisory experience include the $34.6 billion Astra and Zeneca merger, the $6.8 billion Pharmacia & Upjohn merger, Hoechst’s $7 billion acquisition of Marion Merrell Dow; the creation of Syngenta through the merger of the agricultural businesses of AstraZeneca and Novartis; and the $3.1 billion Warner Chilcott LBO.
Stephanie has led financings in life sciences, focusing on biotechnology and specialty pharma. She has worked on more than 15 Initial Public Offerings (IPOs) and has led Secondaries, Convertibles, and Private Placements.
Stephanie currently serves as a Non-Executive Director on the Board of BioPharma Credit PLC and also as a Patron. She earned a B.A. cum laude from Mount Holyoke College and an M.B.A. from the Darden Graduate School of Business at the University of Virginia.